These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6961973)

  • 21. Disposition of [3H]actinomycin D in tumor-bearing mice.
    Galbraith WM; Mellett LB
    Cancer Res; 1976 Apr; 36(4):1242-5. PubMed ID: 1063063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antitumor action of cis-dichlorodiammineplatinum(II) and the effectiveness of a combination with sarcolysine].
    Presnov MA; Konovalova AL; Romanova LF; Sof'ina ZP; Stetsenko AI
    Vopr Onkol; 1978; 24(4):53-60. PubMed ID: 654174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma.
    Rosen G; Tan C; Sanmaneechai A; Beattie EJ; Marcove R; Murphy ML
    Cancer; 1975 Mar; 35(3 suppl):936-45. PubMed ID: 1078642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours.
    Kaye SB; Boden JA; Ryman BE
    Eur J Cancer (1965); 1981 Mar; 17(3):279-89. PubMed ID: 6943028
    [No Abstract]   [Full Text] [Related]  

  • 25. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice.
    Itokazu M; Kumazawa S; Wada E; Wenyi Y
    Cancer Lett; 1996 Oct; 107(1):11-8. PubMed ID: 8913261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapeutic treatment of xenograft Spirocerca lupi-associated sarcoma in a murine model.
    Stettner N; Ranen E; Dank G; Lavy E; Brenner O; Harmelin A
    Comp Med; 2007 Jun; 57(3):267-71. PubMed ID: 17605341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
    Griswold DP; Dykes DJ; Kelley CA; Roberts BJ; Dominick CA
    Cancer Chemother Rep 2; 1974 Mar; 4(1):99-108. PubMed ID: 4524043
    [No Abstract]   [Full Text] [Related]  

  • 28. Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour.
    Miller BE; Miller FR; Machemer T; Heppner GH
    Br J Cancer; 1993 Jul; 68(1):18-25. PubMed ID: 8318410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteogenic sarcoma (osteosarcoma): results of therapy.
    Stein JJ
    Am J Roentgenol Radium Ther Nucl Med; 1975 Mar; 123(3):607-13. PubMed ID: 804824
    [No Abstract]   [Full Text] [Related]  

  • 31. Antitumor tests of amygdalin in transplantable animal tumor systems.
    Stock CC; Tarnowski GS; Schmid FA; Hutchison DJ; Teller MN
    J Surg Oncol; 1978; 10(2):81-8. PubMed ID: 642516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase.
    Horsman MR; Brown DM; Hirst DG; Brown JM
    Br J Cancer; 1986 Feb; 53(2):247-54. PubMed ID: 3006735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
    Houghton JA; Cook RL; Lutz PJ; Houghton PJ
    Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A spontaneous transplantable osteogenic sarcoma in AKR/Ms mice.
    Nakakuki K; Shimokawa K; Yamauchi H; Ojima A
    Gan; 1976 Aug; 67(4):513-21. PubMed ID: 192624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system.
    Radov LA; Korn JH; Haskill JS
    Int J Cancer; 1976 Nov; 18(5):630-8. PubMed ID: 992900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
    Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the cytotoxicity of penicillamine in a rat osteogenic sarcoma.
    Cosolo W; Christophidis N; Drummer OH; Findlay DM
    Clin Exp Pharmacol Physiol; 1986 Oct; 13(10):737-43. PubMed ID: 3467882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
    Brown JM; Hirst DG
    Br J Cancer; 1982 May; 45(5):700-8. PubMed ID: 7082556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
    Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.